IXICO announces £1.9 million new study award

IXICO plc, the AI data analytics company delivering insights in neuroscience, today announces that it has executed a contract to provide neuroimaging services that will support a phase Ib/II clinical trial for Huntington’s disease.

This will build on the Company's existing relationship with the sponsor with whom they contracted a prior safety and efficacy trial in 2019. By deploying innovative imaging biomarker solutions in early phase studies, IXICO enables biopharmaceutical sponsors to accelerate R&D decision making and maximise the value of their drug development pipelines. The new award reflects and reinforces the confidence customers place in IXICO as the trusted and leading neuroimaging partner for Huntington’s disease clinical trials.

This contract was included in management's expectations of performance for the current financial year but adds to the Company's strong order book.

Lammert Albers, Chief Commercial Officer of IXICO, commented: "Huntington’s disease is a devastating rare neurological condition with unmet medical needs. IXICO has worked on numerous HD clinical studies since 2007 and is pleased to build further momentum in our mission to support our clients in delivering data analytics in these challenging areas of rare, neurodegenerative disease. Our services will enable clients to measure the impact of the trialled drugs with greater confidence and potentially unlock new insights into disease progression and drug development.”

 

For further information please contact:

IXICO plc

+44 (0)20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

 

 

 Walbrook PR Ltd

 +44 (0)20 7933 8780

Paul McManus / Lianne Cawthorne /

IXICO@walbrookpr.com

Alice Woodings

 

Date: 27/11/2020